CymitQuimica logo

CAS 918639-08-4

:

Bosutinib monohydrate

Description:
Bosutinib monohydrate is a small molecule tyrosine kinase inhibitor primarily used in the treatment of chronic myelogenous leukemia (CML). It selectively inhibits the BCR-ABL and SRC family kinases, which play crucial roles in the proliferation and survival of cancer cells. The monohydrate form indicates that each molecule of bosutinib is associated with one molecule of water, which can influence its solubility and stability. Bosutinib is characterized by its chemical formula, which includes a complex structure featuring a pyrimidine ring and a phenyl group, contributing to its pharmacological activity. The substance is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Common side effects may include gastrointestinal disturbances, hematological changes, and liver enzyme elevations. As with many targeted therapies, monitoring for adverse effects and drug interactions is essential during treatment. Overall, bosutinib monohydrate represents a significant advancement in the targeted therapy landscape for hematological malignancies.
Formula:C26H29Cl2N5O3·H2O
InChI:InChI=1S/C26H29Cl2N5O3.H2O/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27;/h11-14,16H,4-10H2,1-3H3,(H,30,31);1H2
InChI key:InChIKey=BXPOSPOKHGNMEP-UHFFFAOYSA-N
SMILES:N(C=1C2=C(C=C(OCCCN3CCN(C)CC3)C(OC)=C2)N=CC1C#N)C4=CC(OC)=C(Cl)C=C4Cl.O
Synonyms:
  • Bosutinib monohydrate
  • 3-Quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-, hydrate (1:1)
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 6 products.